Zobrazeno 41 - 50
of 132
pro vyhledávání: '"Rima Al-awar"'
Autor:
Methvin Isaac, Rima Al-awar, Deeba Ensan, Dimitrios Panagopoulos, Jeff A O'Meara, Eleanor Williams, Roslin Adamson, Carlos Zepeda-Velázquez, David Smil, Alex N. Bullock, Ahmed Aman, Taira Kiyota, Jong Fu Wong, Owen G Roberts, Aled M. Edwards
Publikováno v:
Journal of Medicinal Chemistry
Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential
Autor:
Benjamin G. Perry, Rommie E. Amaro, Claudia R. Gordijo, Cora Scholten, Andrew R. Leach, Alexander Hillisch, Kristina Edfeldt, Johanna M. Jansen, Uta Lessel, Gerhard F. Ecker, Rima Al-awar, Matthieu Schapira, Daniel Kuhn, Masoud Vedadi, John D. Chodera, Suzanne Ackloo, Ian Dunham, Robert A. Batey, Wendy D. Cornell, Ingo Muegge, Ulrich A. K. Betz, Hatylas Azevedo, Cristian Bologa, Yoshua Bengio, Kumar Singh Saikatendu, Timothy M. Willson, Aled M. Edwards, Vijayaratnam Santhakumar, John Moult, Alpha A. Lee, Patrick Riley, Michael K. Gilson, Matthew H. Todd, Gerhard Hessler, Cheryl H. Arrowsmith, Andrea Volkamer, Tudor I. Oprea, Anders Hogner, John J. Irwin
Computational approaches in drug discovery and development hold great promise, with artificial intelligence methods undergoing widespread contemporary use, but the experimental validation of these new approaches is frequently inadequate. We are initi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e23031ffc540b08feca94dc5f23b802
https://doi.org/10.33774/chemrxiv-2021-rzq4n
https://doi.org/10.33774/chemrxiv-2021-rzq4n
Autor:
Suzanne Ackloo, Rima Al-awar, Rommie E. Amaro, Cheryl H. Arrowsmith, Hatylas Azevedo, Robert A. Batey, Yoshua Bengio, Ulrich A.K. Betz, Cristian G. Bologa, John D. Chodera, Wendy D. Cornell, Ian Dunham, Gerhard F. Ecker, Kristina Edfeldt, Aled M. Edwards, Michael K. Gilson, Claudia R. Gordijo, Gerhard Hessler, Alexander Hillisch, Anders Hogner, John J. Irwin, Johanna M. Jansen, Daniel Kuhn, Andrew R. Leach, Alpha A. Lee, Uta Lessel, John Moult, Ingo Muegge, Tudor I. Oprea, Benjamin G. Perry, Patrick Riley, Kumar Singh Saikatendu, Vijayaratnam Santhakumar, Matthieu Schapira, Cora Scholten, Matthew H. Todd, Masoud Vedadi, Andrea Volkamer, Timothy M. Willson
Computational approaches in drug discovery and development hold great promise, with artificial intelligence methods undergoing widespread contemporary use, but the experimental validation of these new approaches is frequently inadequate. We are initi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ff20377f97c4f069e09484e87a7f2c
https://doi.org/10.26434/chemrxiv-2021-rzq4n
https://doi.org/10.26434/chemrxiv-2021-rzq4n
Autor:
Jen Dorsey, Yael Babichev, Rosemarie E. Venier, Richard Marcellus, Rima Al-awar, Linda Z. Penn, Albiruni A. Razak, Brendan C. Dickson, Eric Chen, Irene L. Andrulis, Jay Wunder, Rebecca A. Gladdy
Publikováno v:
Clinical Cancer Research. 28:B014-B014
Introduction and Objective: Undifferentiated pleomorphic sarcoma (UPS) and leiomyosarcoma (LMS) are treated with surgery, radiation, and/or chemotherapy. Current drug therapies, such as doxorubicin, have limited response rates and severe toxicities.
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
Autor:
James J. Dowling, Richard Marcellus, Nathaniel D. Anderson, Rosemarie Venier, Anant Maheshwari, Rebecca A. Gladdy, Sheena Guram, Ludmil B. Alexandrov, Mehdi Layeghifard, Marcus Q. Bernardini, Adam Shlien, Nicholas Light, Jay S. Wunder, Rima Al-awar, Irene L. Andrulis, Matthew Zatzman, Kyoko E. Yuki, Brendan C. Dickson, Peter C. Ferguson, Daniel Durocher, Stefan C. Dentro, Carol J. Swallow, Fabio Fuligni, Yael Babichev, Albiruni Ryan Abdul Razak, Moritz Gerstung, Federico Comitani, Marjan Rouzbahman, Huayun Hou, Claire Wunker, J. Drew Thompson
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Leiomyosarcomas (LMS) are genetically heterogeneous tumors differentiating along smooth muscle lines. Currently, LMS treatment is not informed by molecular subtyping and is associated with highly variable survival. While disease site continues to dic
Autor:
John David Konda, Craig Strathdee, Taira Kiyota, David Uehling, Kim Chan Chung, Richard Marcellus, Rima Al-awar, Methvin Isaac, Rodger E. Tiedemann, Chungyee Leung-Hagesteijn, Spencer Ler, Ahmed Aman, Michael Prakesch, Carly Griffin, Andrew X Zhang, Ayome Abibi, Gennady Poda, Babu Joseph, Julie Grouleff, Ratheesh Subramaniam
Publikováno v:
Journal of medicinal chemistry. 64(15)
Both previous and additional genetic knockdown studies reported herein implicate G protein-coupled receptor kinase 6 (GRK6) as a critical kinase required for the survival of multiple myeloma (MM) cells. Therefore, we sought to develop a small molecul
Autor:
Peter J. Ferguson, Mark D. Vincent, Yousef Najajreh, Brian Shilton, Stephen Ritter, Rima Al-awar, Richard Marcellus, Mohammed Mohammed, Methvin Isaac, James Koropatnick
Publikováno v:
Cancer Research. 82:346-346
The inherent genetic instability of cancer cells and the dependence of many tumor types on oncogenic drivers contribute selectivity of anticancer agents against tumor cells. That selectivity is limited, and toxicity to normal cells remains a major li
Autor:
David E. Uehling, Babu Joseph, Kim Chan Chung, Andrew X. Zhang, Spencer Ler, Michael A. Prakesch, Gennady Poda, Julie Grouleff, Ahmed Aman, Taira Kiyota, Chungyee Leung-Hagesteijn, John David Konda, Richard Marcellus, Carly Griffin, Ratheesh Subramaniam, Ayome Abibi, Craig A. Strathdee, Methvin B. Isaac, Rima Al-awar, Rodger E. Tiedemann
Publikováno v:
Journal of Medicinal Chemistry. 65:886-887
Autor:
Rima Al-awar, Taira Kiyota, Matthieu Schapira, M.K. Mann, Carlos Zepeda-Velázquez, Rachel Harding, Ahmed Aman, Cheryl H. Arrowsmith, H.G. Alvarez, A. Dong
USP5 is a deubiquitinase that has been implicated in a range of diseases, including cancer, but no USP5-targeting chemical probe has been reported to date. Here, we present the progression of a chemical series that occupies the C-terminal ubiquitin-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::384a9b2f5329ddc45417c141a66ae99d
https://doi.org/10.1101/2021.05.17.444542
https://doi.org/10.1101/2021.05.17.444542
Autor:
Zachary Blatman, Rose Hurren, Neil MacLean, Ahmed Aman, Taira Kiyota, Kazem Nouri, Rima Al-awar, Moustafa Abohawya, Mehakpreet Saini, Karen Arevalo, Samir H. Barghout, Aaron D. Schimmer, Troy Ketela, Geethu E. Thomas
Publikováno v:
JCI Insight, Vol 6, Iss 5 (2021)
JCI Insight
JCI Insight
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to p